Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 3

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 3
---
’s progress and harness our pipeline of innovative rare disease therapies. Since then, we have launched two rare disease therapies and have been rapidly expanding Zevra’s commercial capabilities. We completed a comprehensive review of our development pipeline to facilitate investment in the most promising, highest return opportunities. At the same time, we have added significant expertise to support the Company’s growth and help us continue to drive operational excellence across our commercial and pre-commercialprograms. Further, we have strengthened Zevra’s balance sheet, providing the Company with ample financial flexibility to continue investing in growth, without needing incremental funding from the capital markets. In late 2024, your Board and management team detailed a clear and comprehensive five-year strategic plan to drive long-term growth and patient impact. We are making significant progress as we successfully drive towards our clear priorities and achieve our vision of positioning Zevra as a leading global rare disease company.

| 1 | Source: FactSet Research Systems Inc. |

The results of our execution speak for themselves: Our strategy has enabled Zevra to deliver superior returns for our stockholders.During the last 1-yearand 2-yearperiods, your Board and management team have delivered total stockholder returns of 54.1% and 14.8%, respectively, all in excess of the comparable biotech sector and the Russell 2000. As seen below, since Mr. McFarlane was appointed CEO in October 2023, Zevra has achieved impressive total stockholder returns of 54.8%. 2 Against this backdrop of significant commercial progress and superior returns, you have an important decision to make at our upcoming Annual Meeting on May 29, 2025. Your Board has two independent directors up for re-election,Wendy L. Dixon, Ph.D., who has served as a director since April 2023, and Tamara A. Favorito, who has served as a director and Chair of the Audit Committee since August 2021 and as our Board Chair since May 2023. Dr. Dixon and Ms. Favorito bring extensive public company board experience, deep knowledge of Zevra, and life sciences management expertise to the Zevra Board. Both directors have contributed valuable perspectives that have helped accelerate the Company’s progress and execution of its strategic goals. Meanwhile, Daniel J. Mangless, an individual stockholder, has nominated Travis C. Mickle, Ph.D., Zevra’s former President and CEO, and Arthur C. Regan, a proxy solicitor, for election to